160 related articles for article (PubMed ID: 2029500)
21. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
22. MEDICA 16 inhibits hepatic acetyl-CoA carboxylase and reduces plasma triacylglycerol levels in insulin-resistant JCR: LA-cp rats.
Atkinson LL; Kelly SE; Russell JC; Bar-Tana J; Lopaschuk GD
Diabetes; 2002 May; 51(5):1548-55. PubMed ID: 11978655
[TBL] [Abstract][Full Text] [Related]
23. Studies on serum lipoproteins of rats developing spontaneous hyperlipidemia.
Gustafsson K; Kiessling H
Artery; 1981; 9(6):456-76. PubMed ID: 7337554
[TBL] [Abstract][Full Text] [Related]
24. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia.
Yang CY; Gu ZW; Xie YH; Valentinova NV; Yang M; Yeshurun D; Quion JA; Gotto AM
Atherosclerosis; 1996 Sep; 126(1):105-16. PubMed ID: 8879439
[TBL] [Abstract][Full Text] [Related]
25. [THE LIPOLYSIS IN PHYLOGENETICALLY EARLY LIPOPROTEINS OF LOW DENSITY AND MORE LATER LIPOPROTEINS OF VERY LOW DENSITY: FUNCTION AND DIAGNOSTIC VALUE OF APOE AND APOC-III].
Rozhkova TA; Titov VN; Amelyushkina VA; Kaba SI; Kukhartchuk VV
Klin Lab Diagn; 2015 Dec; 60(12):4-14. PubMed ID: 27032246
[TBL] [Abstract][Full Text] [Related]
26. Influence of artificial fat emulsions on the composition of serum lipoproteins in humans.
Hailer S; Wolfram G
Am J Clin Nutr; 1986 Feb; 43(2):225-33. PubMed ID: 3080868
[TBL] [Abstract][Full Text] [Related]
27. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients.
Sirtori CR; Montanari G; Gianfranceschi G; Sirtori M; Galli G; Bosisio E
Eur J Clin Pharmacol; 1985; 28(6):619-24. PubMed ID: 3840743
[TBL] [Abstract][Full Text] [Related]
28. Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinanemia.
Olsson AG; Lang PD
Atherosclerosis; 1978 Dec; 31(4):421-8. PubMed ID: 215174
[TBL] [Abstract][Full Text] [Related]
29. Metabolic disorders of serum lipoproteins in endotoxin-poisoned mice: the role of high density lipoprotein (HDL) and triglyceride-rich lipoproteins.
Sakaguchi S
Microbiol Immunol; 1982; 26(11):1017-34. PubMed ID: 6220193
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of action of gemfibrozil on lipoprotein metabolism.
Saku K; Gartside PS; Hynd BA; Kashyap ML
J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
[TBL] [Abstract][Full Text] [Related]
31. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL.
Murdoch SJ; Breckenridge WC
Atherosclerosis; 1995 Dec; 118(2):193-212. PubMed ID: 8770314
[TBL] [Abstract][Full Text] [Related]
32. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
Oscarsson J; Hurt-Camejo E
Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
[TBL] [Abstract][Full Text] [Related]
33. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
34. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
[TBL] [Abstract][Full Text] [Related]
36. Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat.
Elam MB; Wilcox HG; Cagen LM; Deng X; Raghow R; Kumar P; Heimberg M; Russell JC
J Lipid Res; 2001 Dec; 42(12):2039-48. PubMed ID: 11734577
[TBL] [Abstract][Full Text] [Related]
37. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
Chapman MJ; Bruckert E
Atherosclerosis; 1996 Jul; 124 Suppl():S21-8. PubMed ID: 8831912
[TBL] [Abstract][Full Text] [Related]
38. Effects of short-term high carbohydrate, fat-free diet on plasma levels of Apo C-II and Apo C-III and on the Apo C subspecies in human plasma lipoproteins.
Falko JM; Schonfeld G; Witztum JL; Kolar JB; Salmon P
Metabolism; 1980 Jul; 29(7):654-61. PubMed ID: 7382829
[No Abstract] [Full Text] [Related]
39. MDL 29311, a phenolic antioxidant, interferes with the interaction of apoC with VLDL: a possible explanation for its triglyceride-lowering effect.
Sheetz MJ
J Lipid Res; 1995 Dec; 36(12):2609-21. PubMed ID: 8847487
[TBL] [Abstract][Full Text] [Related]
40. Sensitization to insulin induced by beta,beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) in obese Zucker rats in vivo.
Mayorek N; Kalderon B; Itach E; Bar-Tana J
Diabetes; 1997 Dec; 46(12):1958-64. PubMed ID: 9392480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
